Members Wealth LLC Buys New Shares in Cencora, Inc. (NYSE:COR)

Members Wealth LLC bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,430 shares of the company's stock, valued at approximately $348,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. JFS Wealth Advisors LLC increased its holdings in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the period. Banque Transatlantique SA acquired a new stake in shares of Cencora during the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. acquired a new stake in shares of Cencora during the 4th quarter worth approximately $30,000. Kentucky Trust Co bought a new position in Cencora in the fourth quarter valued at approximately $33,000. Finally, WASHINGTON TRUST Co raised its position in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now directly owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This represents a 21.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at $5,241,249.24. This represents a 9.03% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,223 shares of company stock valued at $12,369,767. Company insiders own 10.80% of the company's stock.

Cencora Trading Up 0.3%

Shares of Cencora stock traded up $0.80 on Friday, hitting $291.49. The stock had a trading volume of 3,890,003 shares, compared to its average volume of 1,537,835. The stock has a 50 day moving average of $284.83 and a 200 day moving average of $258.71. The firm has a market capitalization of $56.50 billion, a P/E ratio of 41.46, a PEG ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $3.80 EPS. Sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be given a $0.55 dividend. The ex-dividend date is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Analyst Upgrades and Downgrades

COR has been the topic of a number of research analyst reports. Morgan Stanley set a $288.00 target price on Cencora in a report on Tuesday, April 15th. Citigroup raised their price objective on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Wells Fargo & Company raised their price target on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Finally, UBS Group lifted their price target on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and a consensus target price of $301.18.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.